Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have received an average recommendation of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $50.5556.

Several equities research analysts have commented on VOR shares. HC Wainwright dropped their target price on Vor Biopharma from $32.00 to $31.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. Wall Street Zen upgraded Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wells Fargo & Company began coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st.

Insider Buying and Selling at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 589,257 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares in the company, valued at $75,579,743.19. The trade was a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 3,002,903 shares of company stock valued at $49,412,176 in the last three months. 0.45% of the stock is owned by insiders.

Institutional Trading of Vor Biopharma

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma during the fourth quarter valued at about $36,000. Squarepoint Ops LLC bought a new stake in Vor Biopharma during the third quarter valued at about $230,000. Bank of America Corp DE grew its holdings in Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares during the period. BNP Paribas Financial Markets grew its holdings in Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in Vor Biopharma during the third quarter valued at about $304,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Trading Up 1.1%

Vor Biopharma stock opened at $16.08 on Friday. The business’s fifty day simple moving average is $15.05 and its two-hundred day simple moving average is $14.63. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80. The company has a market capitalization of $871.31 million, a price-to-earnings ratio of -0.04 and a beta of 1.75.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).